Toyota Teams with Tencent, Nissan Joins Forces with Baidu in China AI Drive 
Extraordinary Vietnam fraud case exposes the inherent vulnerabilities of banks 
Asahi Kasei to Build EV Battery Plant in Canada to Supply Key Parts to Honda Motor 
IBM Acquires HashiCorp, Giving Its Hybrid-Cloud Business a Boost 
Hermes Surpasses Expectations with a 17% Surge in First-Quarter Sales 
PUMA and Scuderia Ferrari HP Unveil Miami Limited Edition Collection 
Mercedes Launches 2025 G-Class Electric with Four Motors and Revolutionary Tank Turns 
Hybe Accuses ADOR Subsidiary’s CEO of Breach of Trust 
Family farms are fast disappearing: our research shows how young generations can take them up successfully 
Nestle Reports Sales Dip Amid Price Hikes 
Chipotle Scraps Farmesa Fresh Eatery spinoff, Ghost Kitchen Cease Operations 
Tesla Model 3 Performance Eligible for $7,500 Tax Credit, Launches at $53K 
US SEC Set to Reject Spot Ether ETFs in May Amid Regulatory Hurdles 
Mercedes-Benz to Release Luxury Electric Van in China 
GS25 Launches Limited-Edition Makgeolli ‘Seoul Silver’ in Korea 
Boeing Experiences Quarterly Revenue Drop Amid Production Challenges, Beat Expectations 
New Study Reveals Coke, Pepsi, and Nestle as Top Plastic Polluters 
CORALVILLE, Iowa, Feb. 18, 2016 -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, announced today that its president and chief executive officer, Travis C. Mickle, Ph.D., will present at the RBC Capital Markets 2016 Healthcare Conference being held in New York, NY, February 23-24, 2016. Dr. Mickle will also present at the Cowen & Co. 36th Annual Health Care Conference 2016 being held in Boston, MA, March 7-9, 2016.
Details of KemPharm's presentations are as follows:
RBC Capital Markets 2016 Healthcare Conference
Date: Tuesday, February 23, 2016
Time: 3:35 PM (ET)
Location: The New York Palace Hotel in New York, NY
Cowen & Co. 36th Annual Health Care Conference 2016
Date: Monday, March 7, 2016
Time: 4:40 PM (ET)
Location: The Boston Marriott Copley Place in Boston, MA
The presentations will be webcast and available on the Investor Relations section of KemPharm's website at http://investors.kempharm.com/.
About KemPharm
KemPharm is a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its Ligand Activated Therapy (LAT) platform technology. KemPharm utilizes its LAT platform technology to generate improved prodrug versions of FDA-approved drugs in the high need areas of pain, ADHD and other CNS disorders.
Investor Contacts: Jason Rando / Joshua Drumm, Ph.D. Tiberend Strategic Advisors, Inc. 212-375-2665 / 2664 [email protected] [email protected] Media Contact: Jim Heins Cooney Waters Unlimited 212-886-2221 [email protected]
